ALP AI is a biotech startup redefining biologics development by solving the industry’s "immunogenicity gap." While AI now generates thousands of novel antibody candidates, many fail in the clinic due to unforeseen Anti-Drug Antibody responses. Current testing relies on unreliable animal models or simplistic cell assays that fail to capture complex human B cell reactions.
We provide a platform that combines tonsil-derived immune organoids with AI to detect and prevent immunogenicity in lead optimization. The tonsil data trains our proprietary models to identify hidden epitopes and re-engineer sequences into "biobetters" with minimized risk. We start as a partner to biotechs and PharmaCos and will work on a milestone-based model. Based on that, we will start our own pipeline in the future.
